Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLAUDIT: Pegcetacoplan in wAIHA and CAD
NCT03226678Phase 2Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Sep 2022
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegcetacoplan in warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease (CAD) (2 cohorts), sponsored by Apellis Pharmaceuticals. Primary endpoint: Treatment Emergent Adverse Events. Started Aug 2017; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT03226678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226678.